1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)

Annie Lemelin ,J.C Wells,D.Y.C Heng,N.S Basappa,Takeshi Yuasa ,Rana R Mckay ,Wookwang Cheun ,Toni K Choueiri ,Devon J Boyne ,Sumanta K Pal ,Thomas Powles ,Chris Labaki ,Bernadett Szabados ,Darren R Brenner ,Luís Meza ,Benoît Beuselinck ,Matthew T Warkentin ,Bradley A Mcgregor ,Leopold Ludwig ,Kosuke Takemura

doi:10.1016/j.annonc.2023.09.1132

1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)

Annie Lemelin , J.C Wells + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2023.09.1132

Copy DOI

Journal: Annals of Oncology

Publication Date: Oct 1, 2023

Affiliation: The Cancer Institute Hospital, BC Cancer Agency, Dana-Farber Cancer Institute, University of Calgary, City of Hope, Queen Mary University of London, St Bartholomew's Hospital, Cancer Research UK

#International mRCC Database Consortium #Target Trial Emulation + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)

Full Text